MedTrace Logo

Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1

NCT01347801 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-09-22

No results posted yet for this study

Summary

The purpose of this study is to determine the role of inflammation and the insulin regulating hormone GLP-1 during critical illness.

Conditions

  • Hypoglycaemia

Interventions

DRUG

GLP-1

GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours

DRUG

Placebo (Saline)

Normal saline (NaCl 0,9%)

DRUG

TNF-alfa

1000ng/m2 BSA/hour i.v. infusion for 4-6 hours

OTHER

OGTT

Oral glucose tolerance test with 75 g glucose

OTHER

IVGTT

Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Kirsten Møller, MD, Ph.D., DMSc · Centre of Inflammation and Metabolism

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01347801 on ClinicalTrials.gov